IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+29.45%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$368M
AUM Growth
+$2.11M
(+0.58%)
Cap. Flow
-$72.5M
Cap. Flow
% of AUM
-19.73%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
127
New
24
Increased
22
Reduced
26
Closed
20
Top Buys
| 1 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$10.9M |
| 3 |
Cytokinetics
CYTK
|
$8.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
| 5 |
Pyxis Oncology
PYXS
|
$7.08M |
Top Sells
| 1 |
argenx
ARGX
|
$26.5M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$21.2M |
| 3 |
SPDR S&P Homebuilders ETF
XHB
|
$19.1M |
| 4 |
Nuvalent
NUVL
|
$11.8M |
| 5 |
Disc Medicine
IRON
|
$10.6M |
Sector Composition
| 1 | Healthcare | 98.68% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.86M | 0.53% |
537,925
-208,144
| -28% | -$1.88M |
|
27
MacroGenics
MGNX
$133M
| $4.68M | 0.51% |
+318,167
| New | +$4.68M |
|
28
Xenon Pharmaceuticals
XENE
$3.02B
| $4.61M | 0.51% |
+107,187
| New | +$4.61M |
|
29
Nurix Therapeutics
NRIX
$746M
| $4.41M | 0.48% |
+300,000
| New | +$4.41M |
|
30
Wave Life Sciences
WVE
$1.3B
| $3.64M | 0.4% |
+590,088
| New | +$3.64M |
|
31
Larimar Therapeutics
LRMR
$339M
| $3.33M | 0.36% |
438,528
-164,340
| -27% | -$1.25M |
|
32
Jasper Therapeutics
JSPR
$44.2M
| $3.09M | 0.34% |
+105,175
| New | +$3.09M |
|
33
AEON Biopharma
AEON
$9.1M
| $2.99M | 0.33% |
3,583
| – | – |
|
34
MindMed
MNMD
$688M
| $2.8M | 0.31% |
297,481
-302,519
| -50% | -$2.84M |
|
35
Ventyx Biosciences
VTYX
$185M
| $2.79M | 0.31% |
507,647
+501,733
| +8,484% | +$2.76M |
|
36
Kodiak Sciences
KOD
$523M
| $2.51M | 0.27% |
476,586
+63,705
| +15% | +$335K |
|
37
Tourmaline Bio
TRML
$704M
| $2.48M | 0.27% |
+108,483
| New | +$2.48M |
|
38
uniQure
QURE
$976M
| $2.44M | 0.27% |
469,133
+311,768
| +198% | +$1.62M |
|
39
iBio
IBIO
$16.4M
| $2.44M | 0.27% |
+600,000
| New | +$2.44M |
|
40
Nuvation Bio
NUVB
$1.36B
| $2.31M | 0.25% |
633,282
-589,570
| -48% | -$2.15M |
|
41
Sagimet Biosciences
SGMT
$230M
| $2.24M | 0.25% |
+412,565
| New | +$2.24M |
|
42
Immunic
IMUX
$73.2M
| $2.13M | 0.23% |
+1,612,378
| New | +$2.13M |
|
43
Apellis Pharmaceuticals
APLS
$3.6B
| $2.06M | 0.23% |
35,092
+731
| +2% | +$43K |
|
44
Astria Therapeutics
ATXS
$409M
| $1.98M | 0.22% |
140,687
-234,120
| -62% | -$3.3M |
|
|
LENZ
45
LENZ Therapeutics
LENZ
$1.14B
| $1.9M | 0.21% |
+85,000
| New | +$1.9M |
|
|
ACHL
46
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.8M | 0.2% |
+1,443,181
| New | +$1.8M |
|
47
Voyager Therapeutics
VYGR
$229M
| $1.68M | 0.18% |
180,857
-125,000
| -41% | -$1.16M |
|
|
48
Disc Medicine
IRON
$2.12B
| $1.58M | 0.17% |
25,372
-169,610
| -87% | -$10.6M |
|
49
Insmed
INSM
$30.4B
| $1.39M | 0.15% |
+51,335
| New | +$1.39M |
|
50
RAPT Therapeutics
RAPT
$214M
| $1.39M | 0.15% |
+19,328
| New | +$1.39M |
|